Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Nonalcoholic Fatty Liver Disease

Lingling Ding  1 , Yvonne Oligschlaeger  1 , Ronit Shiri-Sverdlov  1 , Tom Houben  1
Arnold von Eckardstein  1 , Christoph J. Binder  2
, editors.
In: Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets [Internet]. Cham (CH): Springer; 2022.
.
Affiliations
Free Books & Documents
Review

Nonalcoholic Fatty Liver Disease

Lingling Ding et al.
Free Books & Documents

Excerpt

Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome (MetS) and comprises one of the largest health threats of the twenty-first century. In this chapter, we review the current state of knowledge of NAFLD and underline the striking similarities with atherosclerosis. We first describe current epidemiological data showing the staggering increase of NAFLD numbers and its related clinical and economic costs. We then provide an overview of pathophysiological hepatic processes in NAFLD and highlight the systemic aspects of NAFLD that point toward metabolic crosstalk between organs as an important cause of metabolic disease. Finally, we end by highlighting the currently investigated therapeutic approaches for NAFLD, which also show strong similarities with a range of treatment options for atherosclerosis.

PubMed Disclaimer

References

    1. Abdelmalek MF (2016) NAFLD: the clinical and economic burden of NAFLD: time to turn the tide. Nat Rev Gastroenterol Hepatol 13:685–686 - PubMed
    1. Ackerman Z, Oron-Herman M, Grozovski M, Rosenthal T, Pappo O, Link G, Sela BA (2005) Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 45:1012–1018 - PubMed
    1. Afendy A, Kallman JB, Stepanova M, Younoszai Z, Aquino RD, Bianchi G, Marchesini G, Younossi ZM (2009) Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther 30:469–476 - PubMed
    1. Ahn SB, Jang K, Jun DW, Lee BH, Shin KJ (2014) Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 59:2975–2982 - PubMed
    1. Ahrens M, Ammerpohl O, von Schonfels W, Kolarova J, Bens S, Itzel T, Teufel A, Herrmann A, Brosch M, Hinrichsen H, Erhart W, Egberts J, Sipos B, Schreiber S, Hasler R, Stickel F, Becker T, Krawczak M, Rocken C, Siebert R, Schafmayer C, Hampe J (2013) DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 18:296–302 - PubMed

LinkOut - more resources